

Ship to: Patient Physician Other: _____

| | |
|----------------------------|--|
| Patient Information | Patient Last Name: _____ DOB: _____ SSN: _____ |
| | Address: _____ |
| | City: _____ State: _____ Zip: _____ |
| | Phone: _____ Alt Phone: _____ |
| | Email: _____ Alternate Contact Info: _____ |
| | Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female Allergies: _____ |

PLEASE ATTACH COPIES OF FRONT AND BACK OF PATIENT'S PRESCRIPTION INSURANCE CARDS AND MOST RECENT LABS

| | |
|-----------------------------|--|
| Clinical Information | Diagnosis Information for Prior Authorization and Funding Support |
| | Primary Diagnosis: _____ |
| | DX Date (needed for funding): _____ ICD-10 Code: _____ |
| | Secondary Diagnosis: _____ |
| | DX Date (needed for funding): _____ ICD-10 Code: _____ |

| | | | |
|---|---|----------|---------|
| Prescription Information | Injectable Oncology Medication | | |
| | <input type="checkbox"/> Abraxane® <input type="checkbox"/> Cisplatin <input type="checkbox"/> Ellence® <input type="checkbox"/> Gemzar® <input type="checkbox"/> Navelbine® <input type="checkbox"/> Velcade® <input type="checkbox"/> Adriamycin® <input type="checkbox"/> Cytarabine <input type="checkbox"/> Erbitux® <input type="checkbox"/> Herceptin® <input type="checkbox"/> Novantron® <input type="checkbox"/> Vinblastine <input type="checkbox"/> Avastin® <input type="checkbox"/> Cytoxan® <input type="checkbox"/> Ethyol® <input type="checkbox"/> Hycamtin® <input type="checkbox"/> Remicade® <input type="checkbox"/> Vincristine <input type="checkbox"/> BiCNU® <input type="checkbox"/> Dacarbazine <input type="checkbox"/> Etoposide <input type="checkbox"/> Ifex® <input type="checkbox"/> Rituxan® <input type="checkbox"/> Zanosar® <input type="checkbox"/> Bleomycin <input type="checkbox"/> Dactinomycin <input type="checkbox"/> Faslodex® <input type="checkbox"/> Lupron® <input type="checkbox"/> Taxol® <input type="checkbox"/> Zoladex® <input type="checkbox"/> Campath® <input type="checkbox"/> Daunorubicin <input type="checkbox"/> Fludarabine <input type="checkbox"/> MTX <input type="checkbox"/> Taxotere® <input type="checkbox"/> Camptosar® <input type="checkbox"/> Doxil® <input type="checkbox"/> Fluorouracil <input type="checkbox"/> Mitomycin <input type="checkbox"/> Thiotepa <input type="checkbox"/> Other: _____ <input type="checkbox"/> Carboplatin <input type="checkbox"/> Eloxatin® | | |
| | Injectable Oncology Medication Directions: _____ | Dispense | Refills |
| | Dose/Strength: _____ Directions: _____ | | |
| | Infusion Cycle: _____ Date of infusion: _____ | | |
| Additional / Supportive Medications | | | |
| <input type="checkbox"/> Aredia® <input type="checkbox"/> Neupogen® <input type="checkbox"/> Procrit® <input type="checkbox"/> Aranesp® <input type="checkbox"/> Mesna <input type="checkbox"/> Neulasta® <input type="checkbox"/> Epogen® <input type="checkbox"/> Neumega® <input type="checkbox"/> Other: _____ | | | |
| Additional / Supportive Medications Additional / Supportive Medications Directions | Dispense | Refills | |
| | | | |

| | |
|-------------------------------|--|
| Prescriber Information | PRIOR AUTHORIZATION |
| | Prescriber Name: _____ NPI: _____ DEA: _____ LIC#: _____ |
| | Address: _____ |
| | City: _____ Zip: _____ Tel: _____ Fax: _____ |
| | Contact Person: _____ E-Mail: _____ |
| | PRESCRIBER SIGNATURE (Prescriber, please sign and date below) |
| | No stamps. Signature and date must be completed in prescriber's handwriting. NY prescriptions must be submitted via e script. |
| | I authorize Premier Pharmacy and its representatives to act as an agent to initiate and execute prior authorization for the above patient in order to expedite the process, please provide chart notes and most recent labs. |
| | Physician's Signature: _____ <input type="checkbox"/> Dispense as written (DAW) Date: ____/____/____ |
| | <small>IMPORTANT NOTICE: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.</small> |